These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15505149)

  • 1. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review.
    Montané E; Vallano A; Laporte JR
    Neurology; 2004 Oct; 63(8):1357-63. PubMed ID: 15505149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.
    Gracies JM; Nance P; Elovic E; McGuire J; Simpson DM
    Muscle Nerve Suppl; 1997; 6():S92-120. PubMed ID: 9826984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
    Wagstaff AJ; Bryson HM
    Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
    Taricco M; Pagliacci MC; Telaro E; Adone R
    Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review.
    Landau WM
    Neurology; 2005 Jun; 64(11):1989-90; author reply 1989-90. PubMed ID: 15955968
    [No Abstract]   [Full Text] [Related]  

  • 6. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review.
    Olvey EL; Armstrong EP; Grizzle AJ
    Clin Ther; 2010 Dec; 32(14):2282-303. PubMed ID: 21353101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A benefit-risk assessment of baclofen in severe spinal spasticity.
    Dario A; Tomei G
    Drug Saf; 2004; 27(11):799-818. PubMed ID: 15350152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
    Chou R; Peterson K; Helfand M
    J Pain Symptom Manage; 2004 Aug; 28(2):140-75. PubMed ID: 15276195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen.
    Ertzgaard P; Campo C; Calabrese A
    J Rehabil Med; 2017 Mar; 49(3):193-203. PubMed ID: 28233010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review.
    Paisley S; Beard S; Hunn A; Wight J
    Mult Scler; 2002 Aug; 8(4):319-29. PubMed ID: 12166503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy.
    Navarrete-Opazo AA; Gonzalez W; Nahuelhual P
    Arch Phys Med Rehabil; 2016 Apr; 97(4):604-618. PubMed ID: 26321489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dantrolene sodium in chronic spasticity of varying etiology. A double-blind study.
    Luisto M; Möller K; Nuutila A; Palo J
    Acta Neurol Scand; 1982 Apr; 65(4):355-62. PubMed ID: 7102262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.
    Pinder RM; Brogden RN; Speight TM; Avery GS
    Drugs; 1977 Jan; 13(1):3-23. PubMed ID: 318989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).
    Emre M; Leslie GC; Muir C; Part NJ; Pokorny R; Roberts RC
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57(11):1355-9. PubMed ID: 7964811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.
    Mathias CJ; Luckitt J; Desai P; Baker H; el Masri W; Frankel HL
    J Rehabil Res Dev; 1989; 26(4):9-16. PubMed ID: 2600869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].
    Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M
    Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study.
    Dressler D; Rychlik R; Kreimendahl F; Schnur N; Lambert-Baumann J
    BMJ Open; 2015 Dec; 5(12):e009358. PubMed ID: 26719317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal baclofen for severe spasticity secondary to spinal cord injury.
    Lewis KS; Mueller WM
    Ann Pharmacother; 1993 Jun; 27(6):767-74. PubMed ID: 8329801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.